Haymaker Acquisition Corp. III Merges with Biote
June 3, 2022
Haymaker Acquisition Corp. III, a publicly traded SPAC, completed its merger with consumer-directed hormone optimization company Biote (transaction announced Dec 13, 2021; closed May 27, 2022). Biote operates a platform that trains and certifies practitioners and provides practice management software, marketing support and branded nutraceutical products, and had grown a network of roughly 4,700 Biote-certified practitioners in the U.S.
- Buyers
- Haymaker Acquisition Corp. III
- Targets
- Biote
- Industry
- Healthcare Services
- Location
- Texas, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
biote Corp Acquires Asteria Health
January 17, 2024
Healthcare Services
biote Corp. (NASDAQ: BTMD) announced a definitive agreement to acquire F.H. Investments, Inc., doing business as Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The deal is intended to strengthen biote’s control over its supply chain through vertical integration of hormone product manufacturing and expand biote’s capabilities in 503B manufacturing and product development.
-
Bioceres Crop Solutions Merges With Marrone Bio to Create Global Sustainable Agriculture Leader
July 12, 2022
Healthcare Services
Bioceres Crop Solutions Corp. and Marrone Bio Innovations entered into a definitive all-stock merger agreement to combine their businesses. Under the terms, each share of Marrone Bio common stock would be exchanged at a fixed ratio for Bioceres ordinary shares, creating a global platform in biological crop protection, plant health, and seed care solutions.
-
HTL Biotechnology Acquires Modern Meadow's Beauty & Biomedical Division
May 6, 2024
Biotechnology
HTL Biotechnology has acquired the beauty and biomedical division of American company Modern Meadow, including its recombinant proteins platform and leading human recombinant collagen type III (rhCOL3) technology. The deal expands HTL's biopolymer portfolio and R&D/manufacturing capabilities, strengthens its presence in North America, and accelerates development of cosmetic and medical-grade recombinant collagen products.
-
Equillium Acquires Bioniz Therapeutics
February 16, 2022
Biotechnology
Equillium, Inc. (Nasdaq: EQ) acquired privately held Bioniz Therapeutics, obtaining exclusive worldwide rights to Bioniz's pipeline (BNZ-1, BNZ-2, BNZ-3) and proprietary discovery platform in an all-stock transaction (5,699,492 shares, ~19.3% of Equillium outstanding) plus up to $57.5M in development milestones and up to $250M in sales milestones. The acquisition expands Equillium's immunology capabilities and pipeline, adding complementary clinical-stage cytokine-targeting assets and key research and clinical personnel.
-
Bruker Corporation Acquires biocrates life sciences ag
June 3, 2025
Biotechnology
Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.
-
Biobest Group Acquires BioWorks, Inc.
July 10, 2023
Agriculture
Biobest Group has completed its acquisition of BioWorks, Inc., a Victor, New York-based manufacturer and marketer of biopesticides. The deal expands Biobest's biopesticide portfolio and establishes BioWorks' Victor facility as the group's North American manufacturing and marketing hub for biopesticides.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.